Post Market Surveillance and Vigilance in Japan. Medical Device Safety Division, Office of Safety I

Similar documents
FINAL STATUS DOCUMENT

Role and Vision of PMDA

Post Market Surveillance Requirements. SAMED Regulatory Conference 2 December 2015

FINAL DOCUMENT. Global Harmonization Task Force

Guide to Incident Reporting for General Medical Devices and Active Implantable Medical Devices

Medical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by:

Safety Surveillance for Medical Devices

International trend on medical device regulatory convergence

Guide to Incident Reporting for In-vitro Diagnostic Medical Devices

Changing Requirements for Devices//Device Constituent Parts in Combination Products

Post Market Surveillance (PMS): National Competent Authority Report (NCAR) Exchange Programme under IMDRF

Complaint Handling and Medical Device Reporting (MDRs)

Current status on Adverse Event Reporting in Japan

SOP Problems and Adverse Events, Record and Report

GHTF SG2 Guidance: Group work output presentation

Administrative Policies and Procedures. Policy No.: N/A Title: Medical Equipment Management Plan

Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes

STATEMENT. JEFFREY SHUREN, M.D., J.D. Director, Center for Devices and Radiological Health Food and Drug Administration

U-M Hospitals and Health Centers Policies and Procedures

Pediatric Medical Device Development and Safety. Jacqueline N. Francis, MD, MPH Medical Officer, PSRB, ODE, CDRH, FDA

Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation)

Contains Nonbinding Recommendations. Draft Not for Implementation

FDA Medical Device Regulations vs. ISO 14155

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

PMDA EPOCH Toward 2020

Better Medical Device Data Yield Improved Care The benefits of a national evaluation system

University of South Carolina. Unanticipated Problems and Adverse Events Guidelines

Complaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018

Determining and Reporting Adverse Events vs. Product Complaints

Medical Devices and Device-Led Combination Products; Voluntary Malfunction Summary

Accident and Incident Investigation

SOP Title: Reporting Adverse Events and New Safety Information

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS

Modernizing Hospital Adverse Event Reporting

Petition 2011/102 of Carmel Berry and Charlotte Korte

Biomedical IRB MS #

Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER

Software Regulation and Validation

Measurability of Patient Safety

What Does a Consent Form Look Like at Different Reading Levels?

Pharmacovigilance Office of Product Review

The University of Chicago Medicine Privacy Program Accounting of Disclosures Definition Table

University of Chattanooga Respiratory Protection Program. Areas Affected: Employees whose duties require the use of a respirator

IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES

PROMPTLY REPORTABLE EVENTS

A Guide To Safe Blood Transfusion Practice

ADVANCED PLASTIC SURGERY, PLLC. NOTICE OF PRIVACY PRACTICES

The FDA Food Safety Modernization Act of 2009 Section-by-Section Summary

Administrative Policies and Procedures

TITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18

Clinical. Medication Errors and Medicine Defect Reporting SOP. Document Control Summary. Contents

Conduct Field Maintenance on a Hydra-start System Status: Approved

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

GUIDELINES ON MEDICAL DEVICES CLINICAL INVESTIGATIONS: SERIOUS ADVERSE EVENT REPORTING

IMDRF Project: List of international standards recognized by IMDRF management committee members

ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer

Public Input for Changes to Reportable Events Policy

I. Scope This policy defines unanticipated problems and adverse events and establishes the reporting process and timeline.

GOVERNMENT OF THE RUSSIAN FEDERATION. DECREE of December 27, 2012 N On the Rules STATE REGISTRATION OF MEDICAL PRODUCTS

Texas Tech University Health Sciences Center El Paso

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

QA offers significant economic benefits!

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

Maryland Patient Safety Center s Annual MEDSAFE Conference: Taking Charge of Your Medication Safety Challenges November 3, 2011 The Conference Center

THE BOARD OF THE EURASIAN ECONOMIC COMMISSION RESOLUTION. dated December 22, 2015 N 174

SJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office

Clinical Interdepartmental Policy and Procedure

Safety Reporting in Clinical Research Policy Final Version 4.0

MAIMONIDES MEDICAL CENTER. SUBJECT: Medical Equipment Failures and Medical Device Reporting Program

Dissemination of Alerts within the Trust for Reusable Medical Devices

Guideline on good pharmacovigilance practices (GVP)

European CE Marking of Medical Devices. October 2017

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Pars Oil & Gas Company HEALTH, SAFETY AND ENVIRONMENT PROCEDURE. HSE Anomaly Reporting Procedure DOCUMENT ID - PR-74-POGC-002 REVISION 0.

Certified Healthcare Safety Nursing (CHSN) Examination Blueprint/Outline

Regulatory Control of Diagnostics in Tanzania. Hiiti Sillo Ag. Director General Tanzania Food and Drugs Authority

USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION WITHOUT AUTHORIZATION

Health System Action Plan: Injectable Sodium Bicarbonate Shortage and Recall Health System Emergency Management Branch June 26, 2017

PRIVACY IMPACT ASSESSMENT (PIA) For the

Guideline on good pharmacovigilance practices (GVP)

2016 Annual Associate Safety Modules Section 7 Safe Medical Devices Act (SMDA)

Manager. 2. To establish procedures for selecting and acquiring biomedical equipment.

Health and Safety Policy

HIPAA PRIVACY NOTICE

Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements

Patient Registries Initiative Background, Achievements, Next steps

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare

NERC Improving Human Performance

Adverse Events: Thorough Analysis

Personal Protective Equipment Program. Risk Management Services

EPF recommendations for the trilogue on the proposal for regulation on Medical Devices

KP Center for Effectiveness & Safety Research

UV21096 Health and safety in catering and hospitality

Incident Investigation and Reporting Procedures - Code of Practice 3.11

STANDARD OPERATING PROCEDURE

Study Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

Food Safety Modernization Act

Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit

May 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).

Transcription:

Post Market Surveillance and Vigilance in Japan Medical Device Safety Division, Office of Safety I 1

Overview of Adverse Event Reporting 医療機関 Healthcare professionals /facilities 2. Investigation 3. Investigation Manufacturer 1. Reporting an event In 15 or 30 days (depending on seriousness and predictivity) MAH (Marketing Authorization Holders) 4. Adverse event report 2

Definition of Adverse Event Adverse event means unfavorable or harmful. Regardless of occurrence of health hazards 1. Breakage, Malfunction, Poor Operating Performance, etc. 2. Defective Products 3. Problem with device specifications Regardless of occurrence of product problems 4. Health Hazard related to use of the device 5. Inadequate Information on Package Inserts(IFU) Decided to be a cause of operational errors 3

Information included in Adverse Event Reporting Event description What happened to the device What happened to the patient How the patient was treated after the event occurred Technical information How the device was used Maintenance records Experience of the user Opinion of the user Device quality Specification/Durability Manufacturing records Cause analysis Device analysis results Simulation experiments Occurrence of similar events (trends) MAH s conclusions Patient information Age, gender, weight Background Complications Medication/Treatments Clinical examination value Condition Patient outcome Safety measures (as necessary) - Taken measures& Future plans Recall, Repair Written in package inserts/ifu Field safety notice Device modification Improvement of Training program 4

Adverse Event Report (1) - Domestic Case Malfunction, failure, breakage, leak, fault, etc. of a medical device Possibility of Health Damage Serious Description in the package insert/ifu (unanticipated) (anticipated) Report s due date 30 days (Uncomprehended elevation of the incidence rate of AE) 30 days (Except reports shown above) Non-Serious Annual reports - 5

Adverse Event Report (2) - Foreign Case Malfunction, failure, breakage, leak, fault, etc. of a medical device Possibility of Health Damage Serious Description in the package insert/ifu (unanticipated) (anticipated) Report s due date 30 days (Uncomprehended elevation of the incidence rate of AE) 30 days (Except reports shown above) Non-Serious - - 6

Adverse Event Report (3) - Domestic Case Health damage (in case relation with the medical device cannot be denied) Health Damage Description in the package insert/ifu Report s due date Death / Serious Except death (Uncomprehended elevation of the incidence rate of AE) 30 days (Except reports shown above) Non-Serious Annual report - 7

Adverse Event Report (4) - Foreign Case Health damage (in case relation with the medical device cannot be denied) Health Damage Description in the package insert/ifu Report s due date Serious Death (Uncomprehended elevation of the incidence rate of AE) 30 days Non-Serious Except death (Uncomprehended elevation of the incidence rate of AE) 30 days - - 8

Other Reports Adverse Infection Report Health Damage Description in the package insert/ifu Report s due date Domestic Serious Non serious - Foreign Serious Non serious - - Study report :Submitted within 30 days Foreign Field Safety Corrective Action (FSCA) Report: Submitted within 9

Overview of Adverse Event Reporting 医療機関 Healthcare professionals /facilities 2. Investigation 3. Investigation Manufacturer 1. Reporting an event Within 15 or 30 days (depending on seriousness and predictivity) MAH (Marketing Authorization Holders) 4. Adverse event report 6. Consideration of safety measures 5. Share information, Cooperation Ministry of Health, Labour and Welfare (MHLW) 10

Foreign Field Safety Corrective Action (FSCA) Report Manufacturer Collecting information MAH ANSM BfArM EMA FDA MHRA TGA Regulatory Agencies Collecting information FSCA Report (within ) Detailed information about the action taken in foreign countries Actions taken in Japan (recall, repair, provision of information, etc.) 11

Current Status and Issues of Adverse Event Reporting Current Status Adverse Event Reporting is voluntary. Cases without adverse event is not reported. Issues Certain information gathering is needed to take appropriate safety measures. Denominator of patient exposure in medical devices of interest is unknown. 12

Registry broadens limitation of Post-Market Surveillance Registry is : A system constructed to manage patient data centrally and feedback its analysis to healthcare providers. (based on IMDRF Registry Working) Information of all products of interest Add registration in database to conditions for approval. Information of all patients exposure Database Add registration in database to conditions for use. Central management 13

Registry broadens limitation of Post-Market Surveillance Registry makes it possible to : Survey Long Period Use-Result. Calculate accurate incidence of Adverse Events. Conduct thorough monitoring and safety measures to medical devices which were approved under few clinical data. 14

Information gathering system of J-MACS Hospital Register adverse events (1) Death (in ) (2) Device malfunction (in 30 days) (3) Infection (in 30 days) (4) Nerve disorder (in 30 days) (5) Massive bleeding (in 30 days) (6) Other adverse event (periodic report) Database E-mail Definitions of adverse events are harmonized not to cause differences in criteria in each hospital. Information of adverse events MAH Adverse Event Report 15

Case Disconnection of Transdermal Cable of Ventricular Assist Device (VAD) Disconnection of Transdermal Cable occurred frequently in Post-Market. The disconnection is a serious adverse event, because it causes an error on pump function. Ascending Aorta Left Ventricle Transdermal Cable http://duraheart.terumo.co. jp/medical/index.html 16

Case Disconnection of Transdermal Cable of VAD Bend Stress caused disconnection. Old model Improvement of the cable made 23 times stronger than the old model. Improved model https://www.pmda.go.jp/files/000206322.pdf 17

Application of Registry Data Registry Hospital B Hospital A Clinical Record Hospital C Application of Registry Data Database Marketing authorization Re-examination Historical control Publication Guidelines Patient Data 18

Summary Post-Market safety measures are to restore unbalanced riskbenefit balance to a former condition. Safety measures are taken based on domestic and foreign safety information such as adverse event report, FSCA report, etc. reported by MAH. Registry makes it possible to take more appropriate and rational safety measures through more complete information gathering. Registry data is expected to apply not only to safety measures but also to reviews, studies, development of guidelines, etc. 19

Thank you for your attention! 20